Menu OUR WORK IN HEPATITIS C Globally, an estimated 71 million people are living with chronic hepatitis C infection. Most don't know it. CHRONIC HEPATITIS C IS A SERIOUS LIVER DISEASE CAUSED BY THE HEPATITIS C VIRUS (HCV) THAT, OVER TIME, CAN CAUSE LIVER DAMAGE AND CIRRHOSIS (SCARRING OF THE LIVER). IN THE U.S. 3.5 MILLION adults in the U.S. 75% are people born from 1945 to 1965. Approximately 3.5 million adults in the U.S. have chronic HCV infection. More than 75 percent of them are people born from 1945 to 1965. For nearly 30 years, Merck has been at the forefront of the response to chronic HCV, and our team continues to work tirelessly to advance scientific knowledge of this significant global public health issue. IN THE PAST DECADE, MERCK'S CLINICAL DEVELOPMENT PROGRAMS IN CHRONIC HCV INFECTION HAVE: Enrolled Approximately 10,000 Participants Included more than 135 Clinical Trials in Approximately 40 Countries WHAT IT TAKES TO INNOVATE Drs. Eirum Chaudhri and Eliav Barr have worked together at Merck for many years in drug discovery. Learn more about why they find working on chronic hepatitis C so exciting, and what it takes to innovate. READ MORE FROM ELIAV AND EIRUM. RESOURCES Hepatitis C: A Medical - and Social - Diagnosis The Fight Against Hepatitis C Hepatitis C: A Silent Disease and Growing Concern Hepatitis C Infographic Updated Oct. 2017 Copyright. © 2009-2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Forward-Looking Statement Privacy Terms of Use Site Map

Menu Public Policy Position Statements Access & Affordability Access to Our Vaccines Charitable Product Donations IMPLANON® Access initiative for Low-Income Countries IMPLANON® Family Planning Statement Intellectual Property and Access to Medicines in the Developing World ISENTRESS® in Low-Income Countries Medicare Medicines Patent Pool Regulatory Data Protection Social Licensing Approach for Research Development Partnerships for Neglected Tropical Diseases (NTDs) Statement of Guiding Principles on Access to Health Innovation Establishing Effective Systems for Early Resolution of IP Disputes in Pharmaceuticals Health Technology Assessment and Comparative Effectiveness Research Patent Term Extensions Public Health Issues Antibiotic Resistance Biosimilars and Originator Biologics Climate Change Counterfeiting of Medical Products Global Antimicrobial Resistance Action Plan Nanotechnology Pharmaceuticals in the Environment Responsible Disposal of Medicines Supply Chain Security-Global Product Serialization Water Transparency & Responsible Behavior California Supply Chains Act Clinical Trial Ethics Clinical Trials Data Disclosure Conflict Minerals Direct-to-Consumer Advertising Human Rights Independent Expenditures Sharps Management Plan – CalRecycle Trade Association Memberships (Merck) Transparency Disclosures Copyright. © 2009-2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Forward-Looking Statement Privacy Terms of Use Site Map